Divergent regulatory T cell responses to high-dose methylprednisolone and tocilizumab in giant cell arteritis. Issue 133 (December 2022)

• Record Type: Journal Article
• Authors: Scholz, Godehard A.; Fux, Michaela; Christ, Lisa; Iype, Joseena; Banz, Yara; Villiger, Peter M.
• Is Part Of: Journal of autoimmunity. Issue 133(2022)
• Publication Date: 2022-12
• Subjects: Giant cell arteritis -- Methylprednisolone -- Tocilizumab -- Regulatory T cells -- CD15s -- FOXP3 EXON2; Treg cells Regulatory T cells -- MP Methylprednisolone -- TCZ Tocilizumab -- TABs Temporal artery biopsies -- d day -- w week; Autoimmunity -- Periodicals; Autoimmune diseases -- Periodicals; Autoantibodies -- Periodicals; Autoimmune Diseases -- Periodicals; Auto-immunité -- Périodiques; Maladies auto-immunes -- Périodiques; Electronic journals; 616.978005
• DOI: 10.1016/j.jaut.2022.102909
• Languages: English
• ISSNs: 0896-8411

Abstract

Highlights: The clinical data of the proof-of-concept-study about tocilizumab (TCZ) monotherapy after ultra-short glucocorticoid (GC) administration in giant cell arteritis (GCA) was published in The Lancet Rheumatology (https://doi.org/10.1016/S2665-9913(21)00152-1 ). In this manuscript we summarize and analyze the T cell data of the mentioned study: This is the first study analyzing circulating regulatory T cells in newly diagnosed GCA cases prior to GC administration. The study design allowed a comparative analysis of T cell responses to GCs and TCZ. The data suggests a different type of regulatory T cells being involved in control of disease.